CATALENTAI
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

CATALENTAI Trademark

Serial Number: 99603372

CATALENTAI is a trademark filed by R.P. SCHERER TECHNOLOGIES, LLC on January 20, 2026. The trademark is classified under Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

R.P. SCHERER TECHNOLOGIES, LLC (12 trademarks)

14 SCHOOLHOUSE ROAD
SOMERSET, NJ 07083

Entity Type: 16

Trademark Details

Filing Date

January 20, 2026

Registration Date

Not Registered

Published for Opposition

June 30, 2026

Goods & Services

Software as a service (SAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for investigating, resolving deviation life cycle management, root cause analysis management, deviation tracking and reporting management, audit management, change control management, complaint and investigations management, and product annual review management; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for providing quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management, risk assessment, and root cause analysis; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management in regulated manufacturing environments; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for workflow automation of deviation lifecycle processes, namely, initiation, review, approval, corrective and preventive actions (CAPA), and closure; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for audit preparation and support, namely, compiling compliance documentation, and generating audit ready reports; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for change control management, namely, initiating, routing, approving, and implementing changes; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for complaints handling and investigations support, namely, intake, triage, root cause analysis, and corrective and preventive actions (CAPA); Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for product annual review support, namely, aggregating production and quality data, trend analysis, and generating annual product review reports; Pharmaceutical drug development services; Pharmaceutical research and development; Product development in the field of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, vitamins, medicines, pharmaceutical packaging and drug delivery technologies; Research and development of new products for others; Product development consultation; Scientific research consulting in the field of pharmaceuticals and biopharmaceuticals; Technology consultation in the field of pharmaceuticals and new drug development; Custom design and development of chemical reagents and biochemical assays; Development of pharmaceuticals for cell and gene therapies; Research and development and consultation related thereto in the field of over-the-counter drugs; Research and development in the field of pharmaceutical preparations and products for cell therapy, gene therapy, and beauty care; Scientific research consulting; Technology consultation in the field of new drug development for the pharmaceutical industry; Technology consultation in the field of pharmaceutical drug delivery and dosage technologies; Scientific research consulting in the field of pharmaceutical drug delivery and dosage technologies; Testing of pharmaceuticals

Filing History

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 30, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jun 30, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 24, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 30, 2026 CNSA
ASSIGNED TO EXAMINER
May 16, 2026 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 10, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Jan 20, 2026 MAFR
NEW APPLICATION ENTERED
Jan 20, 2026 NWAP